News

This expanded upon the limited data available on risks of precautionary allergen label food introduction for those with allergies, the results of which suggest new possibilities for future allergy management.

This interview with Dr. Chovatiya featured a discussion about new findings from a recent study on epidemiologic data on vitiligo in the US.

The biosimilar month in review highlights the July 1 launch of 7 adalimumab (Humira) biosimilars in the US and the cost-saving potential of increased biosimilar availability.

Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.

Presented at ASRS 2023, study data showed a single, in-office injection of RGX-314 gene therapy may have long-lasting improvements in diabetic retinopathy severity.

While tele-CBT did not lead to significant changes in short-term weight outcomes, it was effective in improving disordered eating behaviors and reducing psychological distress.

Presented at ASRS 2023, additional results from the Pagoda and Pavilion trials suggest a potential benefit of PDS for patients with DME and diabetic retinopathy.

"Depression causes a large public health burden, and alcohol-related behavior is a potentially modifiable risk factor," Dr. Gemma Hammerton writes.

This new data indicates that dupilumab in this patient population had favorable efficacy and safety, though some unique concerns were risk of infection and eosinophilia.

The data from this new study may indicate home NBUVB treatment effectiveness and other benefits such as financial, convenience, and medical benefits.

An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.

At the 48-hour mark, the mean difference between high-dose VX-548 and placebo was 37.8 in the abdominoplasty group and 36.8 in the bunionectomy group, thus demonstrating the drug's pain relief potential.

A multinational study shows people who achieve sustained virologic response still face a 3-fold greater risk or more of mortality due to liver disease or drug-related issues.

The baseline data for the initial 1000 participants recruited into the TX-YDSRN show 79.6% were diagnosed with a primary depressive disorder.

Presented at ASRS 2023, results from the GALE extension study showed crossover to pegcetacoplan treatment from sham stabilized photoreceptor degeneration over 6 months.

Investigators discuss the potential of psychedelic drugs as a new approach to treating mental illnesses, highlighting their therapeutic benefits and the need for further research to understand their effects, safety, and accessibility.

A post hoc analysis of YOSEMITE/RHINE presented at ASRS 2023 suggests faricimab is linked to the faster absence of retinal fluid and fewer injections versus aflibercept in eyes with DME.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

This recent research indicates the necessity for clinicians to be aware of the higher autoimmune disease susceptibility of those with previous rotavirus-associated hospitalization.

This endocrine case report feature a woman with a history of diabetes, hypertension, and marijuana use in her mid 50s brought to the ED for confusion by her friend and neighbor who states that she has been like this for 3 days. Can you determine how best to proceed?

Global estimate prevalence data suggest the virus affects more than 3% of the population, with available treatment and vaccination strategies used too infrequently.

In this interview with Dr. Gold, she describes her team’s recent findings from a phase 4 head-to-head study on risankizumab for psoriasis patients.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

During the early pandemic period, video telehealth use increased among all veteran groups but differences were observed among American Indian/Alaska Native veterans.

Dr. Mikkael Sekeres discusses the approval of quizartinib (Vanflyta) and how it impacts the treatment of acute myeloid leukemia.

This new research suggests a potential need for policymakers to examine nursing home regulations related to staffing and to collaborate with administrators to create better policies.

An analysis of data from more than 80,000 patients using statins suggests the initial benefit on LDL-C reduction was greater for older patients than younger patients.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.